This evening, Queer News Tonight reports that after a new HIV vaccine showed promising results in initial clinical trials, researchers today announced plans to partner with Moderna, manufacturers of one of the COVID-19 vaccines, to continue developing the innovative treatment. The experimental vaccine, developed by the International AIDS Vaccine Initiative (IAVI) and Scripps Research, displayed a 97% response rate among participants in an early stage Phase I trial. Researchers are now partnering with biotechnology company Moderna to explore the development of an mRNA based vaccine. Rather than introducing a weakened or inactivated virus into the human body to trigger an immune response like many vaccines, mRNA vaccines teach the body how to make a protein that triggers an immune response in the body. Researchers say that using this technique to combat the HIV virus, which mutates rapidly and is notoriously hard to target with vaccines, could potentially accelerate the process of HIV vaccine development. According to IAVI, The new vaccine represents a step towards a process that’s been called a “holy grail”.